Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

Amplification of HSD17B1 and ERBB2 in primary breast cancer

Oncogene volume 22, pages 34–40 (2003)Cite this article

Abstract

Estrogens play a crucial role in the development of breast cancer. Estradiol can be produced in the breast tissue in situ, and one of the enzymes involved in this process is 17β-hydroxysteriod dehydrogenase (17β-HSD) type 1 that catalyzes the interconversion of estrone (E1) to the biologically more potent estradiol (E2). The gene coding for 17β-HSD type 1 (HSD17B1) is located at 17q12–21, close to the more studied ERBB2 and BRCA1. The aim of this study was to investigate if HSD17B1 shows an altered gene copy number in breast cancer. We used real-time PCR and examined 221 postmenopausal breast tumors for amplification of HSD17B1 and ERBB2. In all, 32 tumors (14.5%) showed amplification of HSD17B1 and 21% were amplified for ERBB2. Amplification of the two genes was correlated (P=0.00078) and in 14 tumors (44%) with amplification of HSD17B1, ERBB2 was co amplified. The patients with amplification in at least one of the genes had a significantly worse outcome than patients without (P=0.0059). For estrogen receptor (ER)-positive patients who received adjuvant tamoxifen, amplification of HSD17B1 was related to decreased breast cancer survival (P=0.017), whereas amplification of ERRB2 was not. Amplification of HSD17B1 might be an indicator of adverse prognosis among ER-positive patients, and possibly a mechanism for decreased benefit from tamoxifen treatment.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  • Bièche I and Lidereau R . (1995). Genes Chrom. Cancer, 14, 227–251.

  • Bièche I, Olivi M, Champème M-H, Vidaud D, Lidereau R and Vidaud M . (1998). Int J. Cancer, 78, 661–668.

  • Bièche I, Tomasetto C, Regnier CH, Moog-Lutz C, Rio MC and Lidereau R . (1996). Cancer Res., 56, 3886–3890.

  • Dowsett M . (1997). J. Steroid Biochem. Mol. Biol., 61, 261–266.

  • Ellis M, Coop A and Singh B . (2001). J. Clin. Oncol. 19, 3808–3816.

  • Feigelson SH, McKean-Cowdin R, Coetzee GA, Stram DO, Kolonel LN and Henderson BE . (2001). Cancer Res., 61, 785–789.

  • Gunnarsson C, Olsson B and Stål O . (2001). Cancer Res., 61, 8448–8451.

  • Järvinen TA, Tanner M, Rantanen V, Barlund M, Borg Å, Grenman S and Isola J . (2000). Am. J. Pathol., 156, 839–847.

  • Kauraniemi P, Barlund M, Monni O and Kallioniemi A . (2001). Cancer Res., 61, 8235–8240.

  • Labrie F, Luu-Thee V, Lin S-X, Labrie C, Simard J, Breton R and Belanger A . (1997). Steroids, 62, 148–158.

  • Latham C, Zhang A, Nalbanti A, Maner S, Zickert P, Belgen H and Zetterberg A . (2001). Cancer Genet. Cytogenet., 127, 16–23.

  • Luu-Thee V, Zhang Y, Poirier D and Labrie F . (1995). Biochem. Mol. Biol., 55, 581–587.

  • Mannermaa A, Peltoketo H, Winqvist R, Ponder BA, Kiviniemi H, Easton DF, Poutanen M, Isomaa V and Vihko R . (1994). Human Genet., 93, 319–324.

  • Miettinen M, Mustonen M, Poutanen M, Isomaa V and Vihko R . (1996). J. Biochem., 314, 839–845.

  • Miyoshi Y, Ando A, Shiba E, Taguchi T, Tamaki Y and Noguchi S . (2001). Int. J. Cancer, 94, 685–689.

  • Osborne RJ and Hamshere MG . (2000). Cancer Res., 60, 3706–3712.

  • Plummer S, Paris M, Myles J, Tubbs R, Crowe J and Casey G . (1997). Genes Chrom. Cancer, 20, 354–362.

  • Poutanen M, Isomaa V, Letho V-P and Vihko R . (1992). Int. J. Cancer, 50, 386–390.

  • Purohit A, Newman SP and Reed MJ . (2002). Breast Cancer Res., 4, 65–69.

  • Rèvillion F, Bonneterre J and Peyrat JP . (1998). Eur. J. Cancer, 34, 791–808.

  • Sasano H, Frost AR, Saitoh R, Harada N, Poutanen M, Vihko R, Buhm SE, Silverberg SG and Nagura H . (1996). J. Clin. Endocrin. Metabol., 11, 4042–4046.

  • Speirs V, Green AR and Atkin SL . (1998a). J. Steroid Biochem. Mol. Biol., 67, 267–274.

  • Speirs V, Green AR, Walton DS, Kerin MJ, Fox JN, Carleton PJ, Desai SB and Atkin SL . (1998b). Br. J. Cancer, 78, 1421–1429.

  • Speirs V, Walton DS, Hall M-C and Atkin SL . (1999). Br. J. Cancer, 81, 690–695.

  • Stål O, Sullivan S, Sun X-F, Wingern S and Nordenskjöld B . (1994). Cytometry, 16, 160–168.

  • Stål O, Borg Å, Fernö M, Källström A-C, Malmström P, Nordenskjöld B and members of the South Sweden Breast Cancer Group and the Southeast Sweden Breast Cancer Group. (2000). Ann. Oncol., 11, 1545–1550.

  • Suzuki T, Moriya T, Ariga N, Kanazawa M and Sasano H . (2000). Br. J. Cancer, 82, 518–523.

  • Utsumi T, Yoshimura N, Takeuchi S, Ando J, Maruta M, Maeda K and Harada N . (1999). Cancer Res., 59, 377–381.

  • Vihko P, Isomaa V and Ghosh D . (2001). Mol. Cell. Endocrin., 171, 71–76.

  • Yue W, Wang J, Hamilton C, Demers L and Sauten R . (1998). Cancer Res., 58, 927–932.

Download references

Acknowledgements

This study was supported by grants from the Swedish Cancer Society.

Author information

Authors and Affiliations

  1. Department of Biomedicine and Surgery, Division of Oncology, Faculty of Health Sciences, Linköping University, SE-581 85, Linköping, Sweden

    Cecilia Gunnarsson, Marie Ahnström, Kristina Kirschner, Birgit Olsson, Bo Nordenskjöld & Olle Stål

  2. Department of Oncology, Huddinge University Hospital, Stockholm, SE-14 186, Sweden

    Lars Erik Rutqvist

  3. Division of Cytology, Karolinska Hospital, Stockholm, SE-10401, Sweden

    Lambert Skoog

Authors
  1. Cecilia Gunnarsson
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Marie Ahnström
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kristina Kirschner
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Birgit Olsson
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Bo Nordenskjöld
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Lars Erik Rutqvist
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Lambert Skoog
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Olle Stål
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Olle Stål.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gunnarsson, C., Ahnström, M., Kirschner, K. et al. Amplification of HSD17B1 and ERBB2 in primary breast cancer. Oncogene 22, 34–40 (2003). https://doi.org/10.1038/sj.onc.1206078

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1206078

Keywords

This article is cited by

Search

Advanced search

Quick links